9,066 Shares in Sanofi (NASDAQ:SNY) Acquired by Good Steward Wealth Advisors LLC

Good Steward Wealth Advisors LLC purchased a new stake in shares of Sanofi (NASDAQ:SNY - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 9,066 shares of the company's stock, valued at approximately $503,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Brighton Jones LLC grew its holdings in Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock worth $261,000 after acquiring an additional 1,869 shares during the period. Allspring Global Investments Holdings LLC grew its stake in shares of Sanofi by 128.0% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 115,330 shares of the company's stock worth $5,558,000 after purchasing an additional 64,747 shares during the last quarter. Allworth Financial LP raised its holdings in shares of Sanofi by 28.4% in the 4th quarter. Allworth Financial LP now owns 6,524 shares of the company's stock worth $336,000 after purchasing an additional 1,443 shares in the last quarter. Strategic Financial Concepts LLC acquired a new stake in Sanofi during the fourth quarter valued at approximately $667,000. Finally, Kestra Investment Management LLC acquired a new stake in Sanofi during the fourth quarter valued at approximately $84,000. Institutional investors own 14.04% of the company's stock.

Sanofi Stock Up 0.5%

NASDAQ:SNY traded up $0.24 during trading hours on Friday, hitting $47.86. 5,607,107 shares of the company's stock traded hands, compared to its average volume of 2,390,607. The firm has a market cap of $117.37 billion, a P/E ratio of 17.09, a P/E/G ratio of 0.98 and a beta of 0.50. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.69 and a current ratio of 1.37. The stock's fifty day moving average price is $51.31 and its two-hundred day moving average price is $52.00.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.04. The company had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The business's revenue was down 11.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.78 EPS. On average, research analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Stockholders of record on Friday, May 9th were given a dividend of $2.0369 per share. The ex-dividend date of this dividend was Friday, May 9th. This is a boost from Sanofi's previous annual dividend of $1.48. This represents a dividend yield of 3.1%. Sanofi's payout ratio is currently 57.14%.

Analysts Set New Price Targets

SNY has been the topic of several research reports. Hsbc Global Res raised Sanofi to a "strong-buy" rating in a report on Monday, April 28th. BNP Paribas started coverage on Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 target price on the stock. Morgan Stanley set a $56.00 price target on Sanofi in a research report on Monday, June 2nd. Guggenheim restated a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. Finally, The Goldman Sachs Group started coverage on shares of Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating, three have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $61.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.